Chloroquine for mild to moderately active ulcerative colitis: Comparison with sulfasalazine

American Journal of Gastroenterology

Volumn 91, Issue 5, 1996, Pages 917-921

  Goenka, M K ^a,b   Kochhar, R ^a   Tandia, B ^a   Mehta, S K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b NONE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; HYDROXYCHLOROQUINE; SALAZOSULFAPYRIDINE;

ABDOMINAL DISCOMFORT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; IMMUNOMODULATION; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; CHLOROQUINE; COLITIS, ULCERATIVE; FEMALE; HUMANS; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; SULFASALAZINE; TREATMENT OUTCOME;

EID: 0029931113     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Margolin ML, Krumholz MP, Fochios SE, et al. Clinical trials in ulcerative colitis. II. Historical review. Am J Gastroenterol 1988;83: 227-43.
2. Baron JH, Connell AM, Lennard-Jones JE, et al. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet 1962;1:1094-6.
3. Dick AP, Grayson MJ, Carpenter RG, et al. Controlled trial of sulphasalazine in the treatment of ulcerative colitis. Gut 1964;5:437-42.
4. Riis P, Jamum S, Holtz A, et al. The therapeutic effect of methylsalazosulphapyridine versus salazosulphapyridine in active ulcerative colitis. A double blind controlled trial. Scand J Gastroenterol 1979; 14:647-51.
5. Svartz N. The treatment of 124 cases of ulcerative colitis with salazopyrine and attempts of desensitization in cases of hypersensitiveness to sulfa. Acta Med Scand 1948;139(suppl 206):465-72.
6. Klotz V, Maier K, Fischer C, et al. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med 1980;303:1499-502.
7. Dissanayake AS, Truelove SC. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine. Gut 1973;14:923-6.
8. Salmeron G, Lipsky PE. Immunosuppressive potential of antimalarials. Am J Med 1983;75:19-24.
9. Lie SO, Schofield B. Inactivation of lysosomal function in normal cultured human fibroblasts by chloroquine. Biochem Pharmacol 1973; 22:3109-14.
10. Manku MS, Horrobin DF. Chloroquin, quinine, procaine, quinidine, tricyclic antidepressants, and methylxanthines as prostaglandin agonists and antagonists. Lancet 1976;2:1115-7.
11. Hirata F, Corcoran BA, Venkatasubramanian K, et al. Chemoattractants stimulate degradation of methylated phospholipids and release of arachidonic acid in rabbit leukocytes. Proc Natl Acad Sci USA 1979; 76:2640-3.
12. Miyachi Y, Yoshioka A, Imamura S, et al. Antioxidant actions of antimalarials. Ann Rheum Dis 1986;45:244-8.
13. Mayer L, Eisenhardt D. Lack of induction of suppressor T cells by intestinal epithelial cells from patients with inflammatory bowel disease. J Clin Invest 1990;86:1255-60.
14. Sachar DB. Inflammatory bowel disease: Back to the future. Am J Gastroenterol 1990;85:373-6.
15. Mayer L, Turtel P, Present D, et al. Effect of hydroxychloroquine in the treatment of active ulcerative colitis: Results of the open label phase of the controlled trial. Gastroenterology 1991;100:A230.
16. Surawicz CM, Belic L. Rectal biopsy helps to distinguish acute self-limited colitis from idiopathic inflammatory bowel disease. Gastroenterology 1984;86:104-13.
17. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Report on therapeutic trial. Br Med J 1955;2:1041-8.
18. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-9.
19. Habal FM, Greenberg GR. Treatment of ulcerative colitis with oral 5-aminosalicylic acid including patients with adverse reactions to sulfasalazine. Am J Gastroenterol 1988;83:15-9.
20. Rothfield N. Efficacy of antimalarial in systemic lupus erythematosus. Am J Med 1988;85(suppl 4A):53-6.
21. Rynes RI: Hydroxychloroquine treatment of rheumatoid arthritis. Am J Med 1988;85(suppl 4A):18-22.
22. Sayer ME. Use of antimalarial drugs for the treatment of psoriatic arthritis. Am J Med 1992;93:474-5.
23. Galloway CJ, Dean GE, Marsh M, et al. Acidification of macrophage and fibroblast enterocytic vesicles in vitro. Proc Natl Aca Sci USA 1983;80:3334-8.
24. Kirsner JB. Inflammatory bowel disease. Part I. Nature and pathogenesis. Dis Month 1991;37:610-66.
25. Hodgson JHF, Wands JR, Isselbacher KJ. Decreased suppressor cell activity in inflammatory bowel disease. Clin Exp Immunol 1978;32: 451-8.
26. Bland PW, Warren LG. Antigen presentation by epithelial cells of rat small intestine. II. Selective induction of suppressor T cells. Immunology 1986;58:9-14.
27. Portnoy JZ, Callen JP. Opthalmologic aspects of chloroquine and hydroxychloroquine therapy. Int J Dermatol 1983;22:273-8.
28. Easterbrook M. Ocular effects and safety of antimalarial agents. Am J Med 1988;85(suppl 4A):23-9.
29. Taffet SL, Das KM: Sulfasalazine: Adverse effects and desensitization. Dig Dis Sci 1983;28:833-42.
30. Bachrach WH. Sulfasalazine. I. An historical perspective. Am J Gastroenterol 1988;83:487-96.
31. Rao SS, Cann PA, Holdsworth CD. Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant to sulphasalazine. Scand J Gastroenterol 1987;22:332-6.